Page 129 - Read Online

Page 80 Shek et al. Cancer Drug Resist 2019;2:69-81 I http://dx.doi.org/10.20517/cdr.2018.20

41. Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, et al. Influence of FCGRT gene polymorphisms on pharmacokinetics of
therapeutic antibodies. MAbs 2013;5:614-9.
42. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
43. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic
spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
44. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, et al. Predictive role of BRAF mutations in patients with advanced
colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51:587-94.
45. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. Mechanism of activation of the RAF-ERK signaling pathway by
oncogenic mutations of B-RAF. Cell 2004;116:855-67.
46. Xu JM, Wang Y, Wang YL, Wang Y, Liu T, et al. PIK3CA mutations contribute to acquired cetuximab resistance in patients with
metastatic colorectal cancer. Clin Cancer Res 2017;23:4602-16.
47. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA
and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014;53:852-64.
48. Song DD, Zhang Q, Li JH, Hao RM, Ma Y, et al. Single nucleotide polymorphisms rs701848 and rs2735343 in PTEN increases cancer
risks in an Asian population. Oncotarget 2017;8:96290-300.
49. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular
signalling and therapeutic inhibition. Cell Signal 2007;19:2003-12.
50. Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med 2015;5:a006098.
51. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring
Harb Perspect Med 2012;2:a006593.
52. Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577.
53. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, et al. Association of vascular endothelial growth factor and vascular
endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus
bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
54. Bocci G, Loupakis F. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.
Pharmacogenomics 2011;12:1077-80.
55. Cao C, Ying T, Fang JJ, Sun SF, Lv D, et al. Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence
from 11263 subjects. Med Oncol 2011;28:1169-75.
56. Wang K, Liu L, Zhu ZM, Shao JH, Xin L. Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer:
a meta-analysis involving 16,703 individuals. Cytokine 2011;56:167-73.
57. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
58. Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, et al. G12V and G12A KRAS mutations are associated with
poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2016;37:6823-30.
59. Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, et al. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as
predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 2017;17:38.
60. Renaud S, Schaeffer M, Falcoz PE, Seitlinger J, Romain B, et al. Perioperative bevacizumab improves survival following lung
metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12
mutations. Eur J Cardiothorac Surg 2017;51:255-62.
61. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and
predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60:6750-6.
62. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis
2004;7:335-45.
63. Lamy A, Blanchard F, Le Pessot F, Sesboue R, Di Fiore F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice:
results and pitfalls. Mod Pathol 2011;24:1090-100.
64. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations.
Front Oncol 2018;8:86.
65. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and
manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
66. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol
2016;39:98-106.
67. Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to
nivolumab for advanced non-small-cell lung cancer patients. Sci Rep 2017;7:45124.
68. Tan D, Sheng L, Yi QH. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of
ovarian cancer. Cancer Biomark 2018;21:287-97.
69. Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, et al. Functional polymorphisms in PD-L1 gene are associated with the prognosis of
patients with early stage non-small cell lung cancer. Gene 2017;599:28-35.
70. Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, et al. Association of PD-L1 expression and PD-L1 gene polymorphism with poor
prognosis in lung adenocarcinoma and squamous cell carcinoma. Hum Pathol 2017;68:103-11.
71. Wang W, Li F, Mao Y, Zhou H, Sun J, et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of
gastric adenocarcinoma. Hum Genet 2013;132:641-8.